The use of classic hallucinogens/psychedelics in a therapeutic context: healthcare policy opportunities and challenges (2021)
- Authors:
- USP affiliated authors: SANTOS, RAFAEL GUIMARÃES DOS - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP ; ROCHA, JULIANA MENDES - FMRP ; ROSSI, GIORDANO NOVAK - FMRP
- Unidade: FMRP
- DOI: 10.2147/RMHP.S300656
- Subjects: ALUCINOGÊNICOS; RECEPTORES DE DROGA; COGNIÇÃO; HUMOR; POLÍTICAS PÚBLICAS
- Keywords: Hallucinogens; Healthcare; Psychedelics
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Macclesfield
- Date published: 2021
- Source:
- Título: Risk Management and Healthcare Policy
- ISSN: 1179-1594
- Volume/Número/Paginação/Ano: v. 14, p. 901-910, 2021
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc
-
ABNT
SANTOS, Rafael Guimarães dos et al. The use of classic hallucinogens/psychedelics in a therapeutic context: healthcare policy opportunities and challenges. Risk Management and Healthcare Policy, v. 14, p. 901-910, 2021Tradução . . Disponível em: https://doi.org/10.2147/RMHP.S300656. Acesso em: 27 dez. 2025. -
APA
Santos, R. G. dos, Bouso, J. C., Rocha, J. M., Rossi, G. N., & Hallak, J. E. C. (2021). The use of classic hallucinogens/psychedelics in a therapeutic context: healthcare policy opportunities and challenges. Risk Management and Healthcare Policy, 14, 901-910. doi:10.2147/RMHP.S300656 -
NLM
Santos RG dos, Bouso JC, Rocha JM, Rossi GN, Hallak JEC. The use of classic hallucinogens/psychedelics in a therapeutic context: healthcare policy opportunities and challenges [Internet]. Risk Management and Healthcare Policy. 2021 ; 14 901-910.[citado 2025 dez. 27 ] Available from: https://doi.org/10.2147/RMHP.S300656 -
Vancouver
Santos RG dos, Bouso JC, Rocha JM, Rossi GN, Hallak JEC. The use of classic hallucinogens/psychedelics in a therapeutic context: healthcare policy opportunities and challenges [Internet]. Risk Management and Healthcare Policy. 2021 ; 14 901-910.[citado 2025 dez. 27 ] Available from: https://doi.org/10.2147/RMHP.S300656 - Tripping to cope: coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts
- Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic
- Cross-sectional associations between lifetime use of psychedelic drugs and psychometric measures during the COVID-19 confinement: a transcultural study
- Adverse effects after Ayahuasca administration in the clinical setting [Carta]
- The adverse events of ibogaine in humans: an updated systematic review of the literature (2015–2020)
- Classical hallucinogens as antidepressant drugs [Editorial]: a cautionary approach
- The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials
- Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges
- Can hallucinogens alter personality functioning?: results of a clinical trial involving the Pfister’s Colors Pyramids test
- Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: a mechanistic overview
Informações sobre o DOI: 10.2147/RMHP.S300656 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003219349.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
